Draft Community Herbal Monograph On Juniperus Communis L., Aetheroleum
o
EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH
15 March 2010 EMA/HMPC/12402/2010
Committee on Herbal Medicinal Products (HMPC)
Community herbal monograph on Juniperus communis L., aetheroleum
Draft
Herbal medicinal products; HMPC; Community herbal monographs; traditional use; Juniperus communis L., aetheroleum; Juniperi aetheroleum; juniper oil
Discussion in Working Party on Community monographs and Community list (MLWP) |
January 2010 March 2010 |
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation |
15 March 2010 |
End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu |
15 August 2010 |
Rediscussion in Working Party on Community monographs and Community list (MLWP) | |
Adoption by Committee on Herbal Medicinal Products (HMPC) |
Keywords
BG (bälgarski): |
LT (lietuviq. kalba): |
CS (cestina): |
LV (latviesu valoda): |
DA (dansk): |
MT (malti): |
DE (Deutsch): |
NL (nederlands): Jeneverbes |
EL (ellinika): |
PL (polski): |
EN (English): Juniper oil |
PT (português): |
ES (espanol): |
RO (româna): |
ET (eesti keel): |
SK (slovencina): |
FI (suomi): |
SL (slovenscina): |
FR (français): Genièvre (huile essentielle de) |
SV (svenska): |
HU (magyar): |
IS (íslenska): |
IT (italiano): |
NO (norsk): |
An agency of the European Union
7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu
© European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged.
Community herbal monograph on Juniperus communis L., aetheroleum
1. Name of the medicinal product
To be specified for the individual finished product.
2. Qualitative and quantitative composition1' 2
Well-established use |
Traditional use |
With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Juniperus communis L., aetheroleum (juniper oil) i) Herbal substance Not applicable. ii) Herbal preparations Essential oil obtained by steam distillation from the ripe, non-fermented berry cones. |
3. Pharmaceutical form
Well-established use |
Traditional use |
Herbal preparation in liquid dosage forms for oral and cutaneous use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. |
4. Clinical particulars
4.1. Therapeutic indications
Well-established use |
Traditional use |
Oral use Indication 1) Traditional herbal medicinal product to increase the amount of urine to achieve flushing of the |
1 The material complies with the Ph. Eur. monograph (ref.: 1/2008:1832).
2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.
Well-established use |
Traditional use |
urinary tract as an adjuvant in minor urinary tract complaints. Indication 2) Traditional herbal medicinal product for symptomatic relief of digestive disorders such as dyspepsia and flatulence. Cutaneous use Indication 3) Traditional herbal medicinal product as adjuvant in the relief of minor muscle and articular pain. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. |
4.2. Posology and method of administration
Well-established use |
Traditional use |
Posology Oral use Adults Average daily dose 60-100 mg to be taken in 1-3 doses. The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Cutaneous use Adolescents, adults Bath additive 3-4 times weekly 1-1.5 g juniper oil full bath for 10-20 min at 35-38°C The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Duration of use If symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration |
Well-established use |
Traditional use |
Oral use. Cutaneous use. |
4.3. Contraindications
Well-established use |
Traditional use |
Hypersensitivity to the active substance. Severe renal disease including infectious interstitial nephritis, pyelitis and pyelonephritis. Indication 1) Conditions where reduced fluid intake is recommended (e.g. severe cardiac diseases). |
4.4. Special warnings and precautions for use
Well-established use |
Traditional use |
Oral use The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. Cutaneous use The use in children under 12 years of age has not been established due to lack of adequate data. Indications 1) and 2) If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 1) Appropriate fluid intake is recommended. If complaints or symptoms such as fever, dysuria, spasms or blood in the urine occur during the use of the medicinal product, a doctor or a qualified health care professional should be consulted. The use of this product is not recommended in case of oedema due to limited heart and kidney function. Indication 3) In cases of hypertension, a full bath should be used with caution. |
4.5. Interactions with other medicinal products and other forms of interaction
Well-established use |
Traditional use |
None reported. |
4.6. Pregnancy and lactation
Well-established use |
Traditional use |
In the absence of sufficient data, the use during pregnancy and lactation is not recommended. |
4.7. Effects on ability to drive and use machines
Well-established use |
Traditional use |
No studies on the effect on the ability to drive and use machines have been performed. |
4.8. Undesirable effects
Well-established use |
Traditional use |
Allergic skin reactions have been reported. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. |
4.9. Overdose
Well-established use |
Traditional use |
In case of prolonged oral use and overdose, urine will smell of violets. There may be renal irritation and kidney pain, strong diuresis, albuminuria, haematuria, purplish urine, gastrointestinal upsets, increased heartbeat and blood pressure. Rarely symptoms of central stimulation like convulsions occur as well as metrorrhagia and abortion. |
5. Pharmacological properties
5.1. Pharmacodynamic properties
Well-established use |
Traditional use |
Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended. There is limited evidence from non-clinical studies that juniper may influence glucose levels in diabetes |
5.2. Pharmacokinetic properties
Well-established use |
Traditional use |
Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended. |
5.3. Preclinical safety data
Well-established use |
Traditional use |
Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. |
6. Pharmaceutical particulars
Well-established use |
Traditional use |
Not applicable. |
7. Date of compilation/last revision
15 March 2010
Page 6/6
Community herbal monograph on Juniperus communis L., aetheroleum
EMA/HMPC/12402/2010